Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 3/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19744350 | 0.81 | MAPT (0.43) | MAPTMAOBMAOAGRM5NPC1 | |
| SCHEMBL31170819 | 0.81 | MAPT (0.43) | MAPTMAOBMAOAGRM5NPC1 | |
| SCHEMBL3976344 | 0.81 | PARP1 (0.54) | MAPTNOTUMMAOBMAOACYP1A2 | |
| SCHEMBL1265527 | 0.78 | CYP19A1 (0.46) | MAPTMAOBMAOAGRM5PARP1 | |
| SCHEMBL3993011 | 0.78 | LMNA (0.44) | MAPTMAOBMAOAGRM5NPC1 | |
| SCHEMBL29222703 | 0.78 | MAOB (0.39) | MAPTMAOBMAOAGRM5NPC1 | |
| SCHEMBL2370234 | 0.78 | MAOB (0.39) | MAPTMAOBMAOAGRM5NPC1 | |
| SCHEMBL6836952 | 0.78 | MAOA (0.46) | MAPTMAOBMAOAGRM5PARP1 | |
| SCHEMBL1694255 | 0.78 | MAOB (0.42) | MAPTNOTUMMAOBMAOAGRM5 | |
| SCHEMBL10365694 | 0.77 | MAOB (0.36) | MAPTMAOBMAOAGRM5NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118852123-A | Novel heterocyclic compounds as Pol theta inhibitors for the treatment and prevention of cancer and pharmaceutical compositions containing the same | 株式会社大熊制药 | 2024-10-29 | — | — | CN | disclosed |
| CN-112996566-B | Chroman-4-one derivatives for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116496261-A | 4- (1H) -imidazole derivative and medical application thereof | 中国人民解放军军事科学院军事医学研究院 | 2023-07-28 | — | — | CN | disclosed |
| CN-112996566-A | Chroman-4-one derivatives for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE S.Á.R.L. (LU) | 2019-10-01 | — | — | US | disclosed |
| WO-2018154493-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-08-30 | — | — | US | disclosed |
| WO-2017222083-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-12-28 | — | — | WO | disclosed |
| EP-2509950-B1 | 5-Amino-4-hydroxypentoyl amides | JANSSEN R & D IRELAND (IE) | 2015-02-25 | — | — | EP | disclosed |
| US-20120295920-A1 | 5-AMINO-4-HYDROXYPENTOYL AMIDES | JANSSEN SCIENCES IRELAND UC (IE) | 2012-11-22 | — | — | US | disclosed |
| CN-1299365-A | Hygromycin A derivatives | PFIZER PROD INC (US) | 2001-06-13 | — | — | CN | disclosed |
| EP-1075483-A2 | HYGROMYCIN A DERIVATIVES | Pfizer Products Inc. (US) | 2001-02-14 | — | — | EP | disclosed |
| WO-2000021949-A1 | QUINOLONES AS T-RNA SYNTHETASE INHIBITORS AND ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2000-04-20 | — | — | WO | disclosed |
| WO-1999057125-A2 | HYGROMYCIN A DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1999-11-11 | — | — | WO | disclosed |
| US-4282229-A | FOR DIABETIC COMPLICATIONS | PFIZER INC. (US) | 1981-08-04 | — | — | US | disclosed |
| US-4258054-A | ANTIDIABETIC | PFIZER INC. (US) | 1981-03-24 | — | — | US | disclosed |
| US-4210756-A | Tetrahydroquinoline hydantoins for chronic diabetic complications | PFIZER INC. (US) | 1980-07-01 | — | — | US | disclosed |
| US-4209630-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1980-06-24 | — | — | US | disclosed |
| US-4147795-A | ENZYME INHIBITORS | PFIZER INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4117230-A | ANTIDIABETIC AGENTS | PFIZER INC. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, CLCN2, SCNN1G | MAPT 4880/4885NOTUM 3519/4885MAOB 4429/4885 |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, CLCN2, SCNN1G | MAPT 4880/4885NOTUM 3519/4885MAOB 4429/4885 |
| US-20120295920-A1 | 5-AMINO-4-HYDROXYPENTOYL AMIDES | C1S, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-10 | MAPT 2599/4885NOTUM 2148/4885MAOB 3037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.